UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000046345 |
|---|---|
| Receipt number | R000052725 |
| Scientific Title | A study to evaluate the effects of the policosanol derived from the Cuban sugar cane on blood lipid parameters and vascular endothelial function |
| Date of disclosure of the study information | 2021/12/10 |
| Last modified on | 2023/06/12 09:01:07 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
A study to evaluate the effects of the policosanol derived from the Cuban sugar cane on blood lipid parameters and vascular endothelial function
Acronym
A study to evaluate the effects of the policosanol derived from the Cuban sugar cane on blood lipid parameters and vascular endothelial function
Scientific Title
A study to evaluate the effects of the policosanol derived from the Cuban sugar cane on blood lipid parameters and vascular endothelial function
Scientific Title:Acronym
A study to evaluate the effects of the policosanol derived from the Cuban sugar cane on blood lipid parameters and vascular endothelial function
Region
| Japan |
Condition
Condition
Healthy volunteers
Classification by specialty
| Not applicable | Adult |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
To examine the effects of the policosanol derived from the Cuban sugar cane on blood lipid parameters and vascular endothelial function
Basic objectives2
Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
Blood analysis: LDL cholesterol
Key secondary outcomes
Blood analysis: HDL cholesterol, total cholesterol, Triglycerides, hsCRP, apolipoprotein A1, apolipoprotein A2, HPLC lipoprotein fraction
Vascular endothelial function: %FMD
Base
Study type
Interventional
Study design
Basic design
Parallel
Randomization
Randomized
Randomization unit
Individual
Blinding
Double blind -all involved are blinded
Control
Placebo
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
2
Purpose of intervention
Prevention
Type of intervention
| Food |
Interventions/Control_1
Intake of test food for 12 weeks
Interventions/Control_2
Intake of placebo for 12 weeks
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| 65 | years-old | > |
Gender
Male and Female
Key inclusion criteria
1) Males and females whose age of 20 years or more and less than 65 years
2) Subjects whose blood LDL cholesterol levels are 120 mg/dL or more and less than 160 mg/dL
3) Subjects whose blood HDL cholesterol levels are 40 mg/dL or more
4) Subjects receiving a sufficient briefing of the objective and content of the present study, fully understanding and agreeing to voluntarily participate in the study and being able to personally sign a written informed consent
Key exclusion criteria
1) Subjects receiving a medical treatment for chronic diseases (dyslipidemia, high blood pressure, diabetes, etc.)
2) Subjects receiving a medical treatment for serious cardio-vascular, hepatic, renal, respiratory, endocrine or metabolic disorders or having a medical history of these disorders
3) Subjects who have the possibility of developing allergic symptoms by the test food
4) Subjects who take Foods for Specified Health Uses or Foods with Function Claims labeled the effects on lipid metabolism (reducing blood LDL cholesterol, triglycerides, etc.)
5) Subjects who take foods having the effects on lipid metabolism (reducing blood LDL cholesterol, triglycerides, etc.)
6) Subjects who have a smoking habit
7) Female subjects who are pregnant or lactating, or intending to become pregnant during the study
8) Subjects having blood sample of 200 ml or more taken within 1 month, or 400 ml or more within 3 months prior to the start of the present study (e.g. donated blood)
9) Subjects who took part in another clinical study within 3 months prior to the start of the present study or who is currently taking part in another clinical study
10) Subjects deemed unsuitable by the investigator
Target sample size
72
Research contact person
Name of lead principal investigator
| 1st name | Byong Ku |
| Middle name | |
| Last name | Lee |
Organization
RAINBOW AND NATURE KOREA CO., LTD.
Division name
CEO
Zip code
137-873
Address
Hanravivaldi Bldg, 15-10, Gangnam-daero 39-gil, Seocho-gu, Seoul
TEL
+82-2-3011-6462
bklee@rainbownature.com
Public contact
Name of contact person
| 1st name | Tomohiro |
| Middle name | |
| Last name | Sugino |
Organization
Soiken Inc.
Division name
R&D Division
Zip code
560-0082
Address
Senri Life Science Center 13F, 1-4-2, Shinsenri-higashimachi, Toyonaka, Osaka
TEL
06-6871-8888
Homepage URL
sugino@soiken.com
Sponsor or person
Institute
Soiken Inc
Institute
Department
Personal name
Funding Source
Organization
RAINBOW AND NATURE KOREA CO., LTD.
Organization
Division
Category of Funding Organization
Profit organization
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
IRB of Fukuda Clinic
Address
Shin-Osaka brick building 2F, 1-6- 1 Miyahara, Yodogawa-ku, Osaka, Osaka
Tel
06-6398-0203
fukudaclinicIRB@gmail.com
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2021 | Year | 12 | Month | 10 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Completed
Date of protocol fixation
| 2021 | Year | 09 | Month | 18 | Day |
Date of IRB
| 2021 | Year | 09 | Month | 18 | Day |
Anticipated trial start date
| 2021 | Year | 12 | Month | 12 | Day |
Last follow-up date
| 2022 | Year | 05 | Month | 22 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2021 | Year | 12 | Month | 10 | Day |
Last modified on
| 2023 | Year | 06 | Month | 12 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000052725
| Research Plan | |
|---|---|
| Registered date | File name |
| Research case data specifications | |
|---|---|
| Registered date | File name |
| Research case data | |
|---|---|
| Registered date | File name |
